Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 10—October 2026

Dispatch

Emergence of Macrolide-Resistant Bordetella pertussis, Peru, 2025

Eduardo Juscamayta-LópezComments to Author , Faviola Valdivia, Carmen Rodríguez-Cueva, Helen Horna, Yaneth Quispe, María Pía Soto, Segundo Torres, Victor Fiestas Solórzano, Martin Yagui, Vlademir Vicente Cantarelli, Efrain Montilla-Escudero, Víctor Silva, and Ana Raquel Da Costa
Author affiliation: Instituto Nacional de Salud, Lima, Peru (E. Juscamayta-López, F. Valdivia, C. Rodríguez-Cueva, H. Horna, Y. Quispe, M. Pía Soto, S. Torres, V. Fiestas Solórzano, M. Yagui); American Society for Microbiology, Washington DC, USA (V. Vicente Cantarelli, E. Montilla-Escudero, V. Silva, A. Raquel Da Costa).

Main Article

Table

Characteristics of patients with culture-confirmed Bordetella pertussis carrying the macrolide-resistant A2047G mutation in the 23S rRNA gene, Peru, 2025

Sample no. Year of collection Age/sex Region, Province Vaccine status† Maternal Tdap‡ Antimicrobial drug treatment Hospitalized
tf518-24* 2024 9 mo/F Loreto, Datem del Marañón 2 doses Unknown No Unknown
tf048-25 2025 1.6 y/M Puno, Melgar Unknown No No Yes
tf098-25 2025 3 mo/F Lima, Callao 0 No Azithromycin Yes
tf120-25 2025 39.5 y/F Lima, Callao Unknown No Unknown Unknown
tf232-25 2025 16 y/M Cusco, Cusco 1 dose No Azithromycin Unknown
tf303-25 2025 1 mo/F Arequipa, Arequipa 0 Unknown Azithromycin, ampicillin, and amikacin Yes
tf353-25 2025 7 mo/M Cusco, Cusco 3 doses Yes Azithromycin Unknown

*This isolate, collected in late 2024, was considered part of the early phase of the 2025 outbreak. †Number of diphtheria–tetanus–whole cell pertussis–hepatitis B–Hemophilus influenzae type b vaccine doses received before illness onset. ‡Tdap (tetanus–diphtheria–acellular pertussis) vaccination during pregnancy in the patient’s mother.

Main Article

Page created: July 21, 2026
Page updated: September 16, 2026
Page reviewed: September 16, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external